Back to search results

Telehealth for Opioid Use Disorder (OUD) with Buprenorphine

This study is looking at how well a telehealth (remote healthcare) platform called Boulder Care can help people with Opioid Use Disorder (OUD) get treatment. They are testing app-based ways to deliver buprenorphine (a medication used to treat OUD) through telehealth, especially for people in areas with fewer resources or without high-speed internet. The study wants to see if this approach is acceptable, appropriate, and practical for patients. You might be able to join if you have a history of OUD, are starting or recently started buprenorphine treatment, and speak English. You cannot join if you are allergic to buprenorphine or plan to move out of a Boulder Care-affiliated state within 12 months. The study aims to enroll 250 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 250 participants.
What's involved
The study will evaluate intervention acceptability, appropriateness, and feasibility at 48 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 48 weeks to assess the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07169409

Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings

Recruiting
PHASE1Ages 18+InterventionalTreatment
Boulder Care
~250 participants
Updated 2025-09-11 on ClinicalTrials.gov
What's tested:Telemedicine Buprenorphine Treatment

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Intervention Acceptability, Appropriateness, Feasibility
Measured over 48 weeks

Conditions

Opioid Use Disorder

Explore related trials

Opioid Use Disorder

Where it's being run

1 sites across 1 states
Oregon1

Study leadership

  • Andrea Baron, MPH · STUDY_DIRECTOR · Boulder Care

Who to contact

Andrea Baron, MPH
[email protected]
408-483-2766
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

History of Opioid Use Disorder (OUD)
Starting OUD treatment with buprenorphine, or within 45 days of starting or restarting this medication
Speak and understand English

Exclusion

History of allergic reaction to buprenorphine
Plans to move out of a Boulder Care-affiliated state site in the next 12 months (precluding continuation of care)
Untreated mental or medical health conditions that, in the opinion of the participant, would preclude study participation

What this trial measures

  • Intervention Acceptability, Appropriateness, Feasibility48 weeks

    To measure the participant intervention experience, the study team will utilize qualitative interview data with study participants. These data will be organized into the implementation science categories: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM). The study team will determine whether each participant found the intervention to be feasible, acceptable, and/or appropriate. These findings will then be aggregated to better understand how participants experience the implementation of a telemedicine Opioid Use Disorder treatment organization, and will inform a future scaled-up implementation.